Glaucoma Therapeutics Market Overview Of Glaucoma Therapeutics Treatment And Diagnosis Industry Trends By Technology, Pipeline Review 2019 And Key Business Opportunities 2020 – 2027
SEATTLE, March 31, 2021, (PHARMIWEB) — Glaucoma refers to the group of conditions that damages eye’s optic nerve and gets worse over the time. Moreover, in extreme severe cases it may lead to death. According to the International Agency for the Prevention of Blindness: 2017, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1675
Market Dynamics- Drivers
Increasing incidence of glaucoma cases and increasing number of blindness cases are expected to drive growth of the global glaucoma therapeutics market during the forecast period. According to the International Agency for the Prevention of Blindness, 2010 data findings, it is estimated that by 2020, around 80 million people will suffer from glaucoma, with an increase of about 20 million form 2010. Furthermore, in 2010, over 8 million people were bilaterally blind due to glaucoma, which is expected to increase to over 11 million by 2020. Moreover, geriatric population is more prone to glaucoma along with ethnicity and positive family history for glaucoma playing major role in it. According to the American Academy of Ophthalmology (AAO), 2016: the global prevalence of glaucoma is estimated to rise to 76 million in 2020 and 111.8 million in 2040.
Glaucoma may occur among any people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is the major factor increasing prevalence of glaucoma, which in turn, is expected to drive the global glaucoma therapeutics market over the forecast period. For instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the number of people with diabetes aged between 20 to 79 years are increasing worldwide. Among which, Africa (156%) is accounted to register the highest diabetic population, followed by Middle East (110%), South East Asia (84%), Latin and Central America(62%), North America (35%), Europe (16%), and Western Pacific (15%).
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://bit.ly/2O8zmZ2
Market Dynamics- Restraints
Stringent policies concerning marketing and approvals and side effects of glaucoma medications are expected to restrain growth of the global therapeutic market in near future. According to the Glaucoma Research Foundation, 2017 data findings, in the U.S. use of alternative medicines for the treatment of glaucoma has increased 10% to 15% in the past ten years. Furthermore, according to the same source, 50% of the glaucoma patients in the U.S. use some form of alternative therapy in 2017.
On the basis of region, glaucoma therapeutics market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Among regions, North America holds the dominant position in the global glaucoma therapeutics market, followed by Asia Pacific. This is owing to increasing prevalence of diabetes, increasing ocular disorders, and increasing number of blind and visually impaired people in the region. For instance, According to National Federation of the Blind, 2014, an estimated 10 million people in the U.S. are blind or visually impaired. It is estimated that around 1.3 million people are legally blind in the U.S. and the number is projected to increase to 75,000 people annually in the U.S.
Furthermore, Asia Pacific is expected to witness significant growth during the forecast period, owing to proactive government initiatives and awareness programs to eliminate the blindness in the region. For instance, in 2014, HelpAge India, a nonprofit organization, launched a special campaign to address the issue of blindness for underprivileged elderly populations of India.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1675
Glaucoma Therapeutics Market Competitive Landscape
Major players operating in the global glaucoma therapeutics market include Valeant Pharmaceuticals International, Inc., Allergan Inc., Merck KGaA, Fera Pharmaceuticals, LLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Aristo Pharmaceuticals Pvt. Ltd., Santen Pharmaceutical Co., Ltd., Aerie Pharmaceuticals, and Novartis AG. Key players in the market are focusing on organic growth strategies in order to gain maximum market share and retain leading position in the market. For instance, in December 2017, Aerie Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for Rhopressa (netarsudil ophthalmic solution) 0.02%, indicated for lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Glaucoma Therapeutics Market Taxonomy:
By Disease Type
- Primary Open Angle Glaucoma (POAG)
- Primary Angle Closure Glaucoma (PACG)
By Drug Class:
- Alpha adrenergic Agonist
- Beta Blockers
- Prostaglandin Analogs
- Carbonic Anhydrase Inhibitor
- Combined Medication
- Fixed-dose Combinations
By End Users:
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- North America
- Latin America
- Asia Pacific
- Middle East
Table of Content
Global Glaucoma Therapeutics Market Research Report
Section 1: Global Glaucoma Therapeutics Industry Overview
Section 2: Global Economic Impact on Glaucoma Therapeutics Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Glaucoma Therapeutics Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Glaucoma Therapeutics Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire